U.S. STEM CELL, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-10-24: Form 8-K; Period of report 2014-10-23; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2014-10-10: Form 8-K; Period of report 2014-10-07; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2014-07-11: Form 8-K; Period of report 2014-07-11; Description 8.01 Other Events; Details 8.01.
- 2014-04-07: Form 8-K; Period of report 2014-04-02; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-10-24 | 8-K | 2014-10-23 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On October 23, 2014 (the “Closing Date”), Bioheart, Inc., a Florida corporation (the “Company”), entered into a common stock purchase agreement dated as of the Closing Date (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (the “Investor”). 3.02 Reference is made to the disclosure set forth under Item 1.01 of this Report, which disclosure is incorporated herein by reference. 8.01 On October 24, 2014, the Company issued a press release announcing it had entered into the Purchase Agreement and Registration Rights Agreement, a copy of which is attached to this Report as Exhibit 99.1. | e61149_8k.htm |
| 2014-10-10 | 8-K | 2014-10-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On October 7, 2014 (the “Closing Date”), Bioheart, Inc., a Florida corporation (the “Company”), entered into a securities purchase agreement dated as of the Closing Date (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (“Magna”). 2.03 The disclosure set forth under Item 1.01 of this Report is incorporated by reference into this Item. | d31725.htm |
| 2014-07-11 | 8-K | 2014-07-11 | 8.01 Other Events | 8.01 The Company, as part of the general corporate restructuring and provide management with enhanced financial alternatives in obtaining additional financing, has been eliminating pre-exiting debt obligations through the conversion of such debt obligations to equity, valued oat $0.04 per share. | d31492.htm |
| 2014-04-07 | 8-K | 2014-04-02 | 1.02 Termination of a Material Definitive Agreement | 1.02 In June 2000, we entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to us a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. | d31272.htm |